Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17100893 | 0.91 | SIGMAR1 (0.58) | SIGMAR1MAPTHRH3HTR1ATP53 | |
| SCHEMBL21905668 | 0.90 | MAPT (0.48) | SIGMAR1DRD2DRD4MAPTGAA | |
| SCHEMBL17100763 | 0.85 | SIGMAR1 (0.56) | SIGMAR1DRD2DRD4HRH3HTR1A | |
| SCHEMBL17100673 | 0.84 | ALDH1A1 (0.57) | SIGMAR1DRD2DRD4MAPTGAA | |
| SCHEMBL17100681 | 0.83 | MAPT (0.53) | MAPTGAATHRBTP53NPC1 | |
| SCHEMBL17100580 | 0.83 | MAPT (0.52) | DRD2DRD4MAPTGAATHRB | |
| SCHEMBL17100747 | 0.82 | SIGMAR1 (0.56) | SIGMAR1DRD2DRD4MAPTHRH3 | |
| SCHEMBL14486630 | 0.82 | SIGMAR1 (0.56) | SIGMAR1DRD2DRD4MAPTHRH3 | |
| SCHEMBL17100809 | 0.80 | ALDH1A1 (0.54) | SIGMAR1DRD2DRD4MAPTGAA | |
| SCHEMBL17100698 | 0.80 | MAPT (0.59) | SIGMAR1DRD2DRD4MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | claimed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | claimed |
| EP-3119774-A1 | OXADIAZOLE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | claimed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | claimed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| EP-3119774-A1 | OXADIAZOLE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562869-B2 | Oxadiazole compounds | OXA1L, PSEN1, MAPT | SIGMAR1 1261/4885DRD2 1401/4885DRD4 1514/4885 |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | SIGMAR1 1288/4885DRD2 1449/4885DRD4 1557/4885 |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | SIGMAR1 1261/4885DRD2 1401/4885DRD4 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.